Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Critical Appraisal of Amyloid Lowering Agents in AD
Boris Decourt, Fadel Boumelhem, Evans D. Pope, et al.
Current Neurology and Neuroscience Reports (2021) Vol. 21, Iss. 8
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
Mingchao Shi, Fengna Chu, Feiqi Zhu, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 192
Aducanumab: evidence from clinical trial data and controversies
Rajesh R. Tampi, Brent P. Forester, Marc Agronin
Drugs in Context (2021) Vol. 10, pp. 1-9
Open Access | Times Cited: 150
Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First: The Chicken or the Egg?
Elena Tamagno, Michela Guglielmotto, Valeria Vasciaveo, et al.
Antioxidants (2021) Vol. 10, Iss. 9, pp. 1479-1479
Open Access | Times Cited: 143
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Teresa Pardo-Moreno, Anabel González‐Acedo, Antonio Rivas-Domínguez, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1117-1117
Open Access | Times Cited: 129
Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
Charles Withington, Raymond Scott Turner
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 86
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Eric L. Ross, Marc S. Weinberg, Steven E. Arnold
JAMA Neurology (2022) Vol. 79, Iss. 5, pp. 478-478
Open Access | Times Cited: 79
The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation
Mohammad Sobhan Karvandi, Farzam Sheikhzadeh Hesari, Amir Reza Aref, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 46
Puerarin: a potential natural neuroprotective agent for neurological disorders
Xue Liu, Rui Huang, Jiye Wan
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114581-114581
Open Access | Times Cited: 46
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
A. Y. Kim, Salman Al Jerdi, Ryan B. MacDonald, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 18
Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review
Hannah W. Haddad, Garett W. Malone, Nicholas J. Comardelle, et al.
Health psychology research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 49
Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges
Tong Wu, Lin Ding, Ya‐Qian Cheng, et al.
Aging and Disease (2022) Vol. 13, Iss. 6, pp. 1745-1745
Open Access | Times Cited: 39
Myelin in Alzheimer’s disease: culprit or bystander?
Michel Maître, Hélène Jeltsch‐David, Nwife Getrude Okechukwu, et al.
Acta Neuropathologica Communications (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 35
Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development
Rouen Brockmann, Ioanna Nixon, Bryan L. Love, et al.
The Lancet Regional Health - Americas (2023) Vol. 20, pp. 100467-100467
Open Access | Times Cited: 32
Navigating the dementia landscape: Biomarkers and emerging therapies
Shubhrat Maheshwari, Aditya Singh, Valeed Ahmad Ansari, et al.
Ageing Research Reviews (2024) Vol. 94, pp. 102193-102193
Closed Access | Times Cited: 14
Pathogenesis, Diagnostics, and Therapeutics for Alzheimer's Disease: Breaking the Memory Barrier
Pushpa Tryphena Kamatham, Rashi K. Shukla, Dharmendra Kumar Khatri, et al.
Ageing Research Reviews (2024) Vol. 101, pp. 102481-102481
Open Access | Times Cited: 13
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Grant A. Krafft, Jasna Jerecı̀ć, Eric Siemers, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 28
Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer’s Disease: Recent Trends and Future Development
Bhavarth P. Dave, Yesha Shah, Kunal G. Maheshwari, et al.
Cellular and Molecular Neurobiology (2023) Vol. 43, Iss. 8, pp. 3847-3884
Closed Access | Times Cited: 16
Effect of hormone replacement therapy on amyloid beta (Aβ) plaque density in the rhesus macaque amygdala
Maria‐Luisa Appleman, Jeremy L. Thomas, Alison R. Weiss, et al.
Frontiers in Aging Neuroscience (2024) Vol. 15
Open Access | Times Cited: 7
Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer’s Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring
So Yeong Jeong, Chong Hyun Suh, Sang Joon Kim, et al.
Korean Journal of Radiology (2024) Vol. 25, Iss. 8, pp. 726-726
Open Access | Times Cited: 7
Skeletal muscle atrophy‐induced hemopexin accelerates onset of cognitive impairment in Alzheimer's disease
Tsukasa Nagase, Chihiro Tohda
Journal of Cachexia Sarcopenia and Muscle (2021) Vol. 12, Iss. 6, pp. 2199-2210
Open Access | Times Cited: 34
Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound
Liyu Chen, Esteban Cruz, Lotta E. Oikari, et al.
Advanced Drug Delivery Reviews (2022) Vol. 189, pp. 114517-114517
Closed Access | Times Cited: 23
The Pursuit of the “Inside” of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer’s Disease?
Nobumasa Takasugi, Masato Komai, Nanaka Kaneshiro, et al.
Cells (2023) Vol. 12, Iss. 3, pp. 454-454
Open Access | Times Cited: 15
Drug trial for Alzheimer’s disease is a game changer
Eric M. Reiman
Nature (2023) Vol. 615, Iss. 7950, pp. 42-43
Closed Access | Times Cited: 13
Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects
Jun Li, Wang Liao, Dongqing Huang, et al.
Coordination Chemistry Reviews (2023) Vol. 495, pp. 215375-215375
Closed Access | Times Cited: 13
A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases
Stefania Merighi, Pier Andrea Borea, Katia Varani, et al.
Current Medicinal Chemistry (2021) Vol. 29, Iss. 24, pp. 4138-4151
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top